{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T22:10:15Z","timestamp":1740780615012,"version":"3.38.0"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T00:00:00Z","timestamp":1292371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Acute B\u2010cell leukemia (B\u2010ALL) is a rare form of pediatric leukemia characterized by a very high\u2010proliferation index, rapid clinical progression, and a high frequency of central nervous system (CNS) involvement. Commonly, it is treated in the clinical trials for Burkitt lymphoma, of which it represents the leukemic counterpart.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Children with B\u2010ALL diagnosed between 1988 and 1999 were enrolled in the AIEOP\u20108805 protocol. Treatment included six high\u2010dose chemotherapy courses. No prophylactic CNS irradiation was administered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty\u2010five consecutive patients were enrolled in the study. L3 morphology was observed in 57 of 65 patients (88%). Twenty\u2010five children (38%) had tumor mass in addition to massive bone marrow infiltration; 11 children (17%) had CNS disease at diagnosis. Sixty\u2010two patients obtained complete morphological remission of which 13 suffered a relapse, including 3 with initial CNS involvement. Ten\u2010year overall survival and event\u2010free survival were 77% and 75%, respectively. Neither relevant long\u2010term toxicity nor second malignancies were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The AIEOP\u20108805 confirmed that short high\u2010dose chemotherapy is highly effective for the treatment of B\u2010ALL without significant long\u2010term adverse sequelae. Therapy modifications to reduce relapse rate, such as the use of anti\u2010CD20 monoclonal antibody and more effective CNS treatment, are being tested. Pediatr Blood Cancer 2011;56:544\u2013550. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22787","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T17:50:10Z","timestamp":1292435410000},"page":"544-550","source":"Crossref","is-referenced-by-count":3,"title":["Long\u2010term results of AIEOP\u20108805 protocol for acute B\u2010cell lymphoblastic leukemia of childhood"],"prefix":"10.1002","volume":"56","author":[{"given":"Marta","family":"Pillon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Aric\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Citterio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Micalizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Testi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Barisone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rondelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Rosolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the NHL\u2010Committee of the Italian Association of Pediatric Hematology, Oncology (AIEOP)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,15]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"405","article-title":"Advanced stage (III\u2010IV) Burkitt's lymphoma ad B\u2010cell acute lymphoblastic leukemia in children: Kinetics and pharmacologic rationale for treatment and recent results (1979\u20131983)","volume":"60","author":"Murphy SB","year":"1985","journal-title":"IARC Sci Publ"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"e_1_2_6_4_2","first-page":"6","article-title":"Clinical and biological heterogeneity of childhood B cell acute lymphocytic leukemia: Implications for clinical trials","volume":"4","author":"Sullivan MP","year":"1990","journal-title":"Leukemia"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/beha.2002.0231"},{"key":"e_1_2_6_6_2","first-page":"135","article-title":"BFM study 1981\/83 on the treatment of highly malignant non\u2010Hodgkin's lymphoma in children: Results of therapy stratified according to histologic immunological type and clinical stage","volume":"196","author":"Muller\u2010Weihrich S","year":"1984","journal-title":"Klin Padiatr"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.10.2471.2471"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0026-895X(25)14873-6","article-title":"S\u2010phase cells of rapidly growing and resting populations. Differences in response to methotrexate","volume":"5","author":"Hryniuk WM","year":"1969","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2307\/2344317"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65463-6"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04134.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.4.661"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2390"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199903)32:3<225::AID-MPO12>3.0.CO;2-N"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200101000-00008"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10262"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood.V81.8.2003.2003","article-title":"Curability of relapsed childhood B\u2010cell non\u2010Hodgkin's lymphoma after intensive first line therapy: A report from the Societe Francaise d'Oncologie Pediatrique","volume":"81","author":"Philip T","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21753"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290017051"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705948"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200304000-00013"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.382"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402828"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.3159"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0177"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22787","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T21:13:29Z","timestamp":1740777209000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,15]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1002\/pbc.22787"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22787","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"type":"print","value":"1545-5009"},{"type":"electronic","value":"1545-5017"}],"subject":[],"published":{"date-parts":[[2010,12,15]]}}}